Huarun Pharmaceutical: First Quarter Report for 2026

SZSIApr 24 00:00 · Announcements

Huarun Pharmaceutical: 2025 Annual Report

SZSIApr 24 00:00 · Announcements

Huarun Pharmaceutical: Summary of the 2025 Annual Report

SZSIApr 24 00:00 · Announcements

Huaren Pharmaceutical (300110.SZ): Q1 net profit attributable to shareholders was RMB 15.9586 million, a year-on-year decrease of 0.44%.

Gelonghui, April 23rd - Huaren Pharmaceutical (300110.SZ) released its Q1 2026 report. During the reporting period, the company achieved operating revenue of 310 million yuan, representing a year-on-year increase of 2.14%; net profit attributable to shareholders of the listed company was 15.9586 million yuan, representing a year-on-year decrease of 0.44%; net profit attributable to shareholders of the listed company after excluding non-recurring gains and losses was 16.5123 million yuan, representing a year-on-year increase of 34.72%; basic earnings per share were 0.0135 yuan.

Gelonghui FinanceApr 23 21:31

Stocks in the A-share market showed unusual movements as a collective rise occurred among flu-related concept stocks, amid reports that China's influenza positivity rate has increased for three consecutive weeks.

Gelonghui, April 15 | The A-share market's flu concept stocks collectively rose. By the close of trading, BrightGene Bio-Medical Technology surged by 20%, Innovax Biotech increased by over 14%, Conba Pharmaceutical, Peking University Medicine, Hisun Pharmaceuticals, Double-Crane Pharmaceuticals, and Harbin Pharmaceutical Group all surged by 10%, Corally Medical rose by over 7%, Jiande Zhixin and Fengyuan Pharmaceutical increased by over 6%, Huaren Pharmaceuticals grew by over 5%, Kangzhi Pharmaceutical, Hotgen Biotech, Yipinhong Pharmaceutical, and Kelun Pharmaceuticals rose by over 4%. In terms of news, according to recent data released by the Chinese Center for Disease Control and Prevention (CDC) on national sentinel surveillance of acute respiratory infectious diseases, the positive rate of national influenza virus detection has risen for three consecutive weeks. The latest monitoring data shows: 20

Gelonghui FinanceApr 15 15:05

Express News | Huarun Pharmaceuticals: Matters related to the change of actual controller are still in the planning process, and the specific implementation plan is still under negotiation.

BreakingsApr 14 07:27